1. Home
  2. ATRA vs MAGN Comparison

ATRA vs MAGN Comparison

Compare ATRA & MAGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATRA
  • MAGN
  • Stock Information
  • Founded
  • ATRA 2012
  • MAGN 1864
  • Country
  • ATRA United States
  • MAGN United States
  • Employees
  • ATRA N/A
  • MAGN N/A
  • Industry
  • ATRA Biotechnology: Biological Products (No Diagnostic Substances)
  • MAGN Paper
  • Sector
  • ATRA Health Care
  • MAGN Basic Materials
  • Exchange
  • ATRA Nasdaq
  • MAGN Nasdaq
  • Market Cap
  • ATRA 65.1M
  • MAGN 67.4M
  • IPO Year
  • ATRA 2014
  • MAGN N/A
  • Fundamental
  • Price
  • ATRA $11.40
  • MAGN $17.83
  • Analyst Decision
  • ATRA Buy
  • MAGN
  • Analyst Count
  • ATRA 6
  • MAGN 0
  • Target Price
  • ATRA $26.50
  • MAGN N/A
  • AVG Volume (30 Days)
  • ATRA 77.5K
  • MAGN 689.1K
  • Earning Date
  • ATRA 11-12-2024
  • MAGN 02-15-2025
  • Dividend Yield
  • ATRA N/A
  • MAGN N/A
  • EPS Growth
  • ATRA N/A
  • MAGN N/A
  • EPS
  • ATRA N/A
  • MAGN N/A
  • Revenue
  • ATRA $100,439,000.00
  • MAGN $2,175,000,000.00
  • Revenue This Year
  • ATRA $1,346.63
  • MAGN N/A
  • Revenue Next Year
  • ATRA N/A
  • MAGN N/A
  • P/E Ratio
  • ATRA N/A
  • MAGN $29.96
  • Revenue Growth
  • ATRA 2111.34
  • MAGN N/A
  • 52 Week Low
  • ATRA $6.50
  • MAGN $15.86
  • 52 Week High
  • ATRA $39.50
  • MAGN $35.23
  • Technical
  • Relative Strength Index (RSI)
  • ATRA 51.71
  • MAGN N/A
  • Support Level
  • ATRA $9.13
  • MAGN N/A
  • Resistance Level
  • ATRA $13.64
  • MAGN N/A
  • Average True Range (ATR)
  • ATRA 0.96
  • MAGN 0.00
  • MACD
  • ATRA -0.27
  • MAGN 0.00
  • Stochastic Oscillator
  • ATRA 50.33
  • MAGN 0.00

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Share on Social Networks: